Clinical Thresholds of Double-strand Breaks in Sperm's DNA in ART (DSBs)
A Prospective Trial Assessing the Impact of Double-strand Breaks on ART Outcomes and Predicting Its Clinical Thresholds
The goal of this prospective observational study is to learn about the impact of double-strand sperm DNA fragmentation (dsSDF) on assisted reproductive technology (ART) outcomes and to derive clinically relevant threshold values for dsSDF and global sperm DNA fragmentation (SDF) in couples undergoing intracytoplasmic sperm injection (ICSI). The main questions it aims to answer are:
- Can clinically relevant threshold values of dsSDF and global SDF predict live birth rates following ICSI?
- Does elevated dsSDF reduce live birth rates following ICSI? Participants undergoing ICSI as part of their routine fertility treatment will provide semen samples for global SDF and dsSDF assessment using the R10 Plus and R11 Plus kits, respectively, analysed using the LensHooke® X12 platform before and after sperm preparation. SDF and dsSDF assessments will be performed both prior to and following sperm washing for each participant. Embryos will be assessed from fertilization through embryo development, and following embryo transfer, participants will be prospectively followed for clinical outcomes ranging from biochemical pregnancy to live birth.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This prospective, two-centre observational study is designed to evaluate the impact of double-strand sperm DNA fragmentation (dsSDF) on assisted reproductive technology (ART) outcomes and to derive clinically relevant threshold values for dsSDF and global sperm DNA fragmentation (SDF) in couples undergoing intracytoplasmic sperm injection (ICSI). Although conventional sperm DNA fragmentation assays assess overall DNA damage, they do not differentiate between single- and double-strand DNA breaks. Emerging evidence suggests that dsSDF represents a more severe form of genomic damage with limited oocyte repair potential and may therefore have a greater impact on embryological and reproductive outcomes, particularly live birth.
A total of 484 infertile couples undergoing ICSI treatment at two tertiary IVF centres in India will be prospectively recruited based on predefined eligibility criteria. Semen samples will be collected on the day of ICSI following 2-3 days of sexual abstinence. Global SDF and dsSDF assessments will be performed using the LensHooke® X12 platform with the R10 Plus and R11 Plus kits, respectively. SDF testing will be conducted both before and after sperm preparation to evaluate the impact of sperm washing on DNA fragmentation parameters.
Embryos derived from enrolled participants will be prospectively assessed from fertilization through embryo development. Following embryo transfer, participants will be prospectively followed for clinical outcomes including biochemical pregnancy, clinical pregnancy, ongoing pregnancy, miscarriage, and live birth.
Receiver operating characteristic (ROC) curve analysis will be used to derive clinically relevant threshold values for dsSDF and global SDF. Multivariable regression analyses will additionally be performed to evaluate the predictive value of dsSDF and global SDF for ART outcomes while adjusting for potential confounding factors. The findings of this study are expected to improve the clinical interpretation of sperm DNA damage assessment and support the integration of dsSDF into individualized reproductive care.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Vipin Chandra, M.B.B.S., D.G.O.
- Telefonní číslo: 918567971239
- E-mail: drvipinchandra@indiraivf.in
Studijní místa
-
-
Karnataka
-
Bangalore, Karnataka, Indie, 560041
- Indira IVF Hospital
-
Kontakt:
- Jishnu PS, MSc
- Telefonní číslo: 919645062072
- E-mail: jishnu.ps@indiraivf.in
-
Dílčí vyšetřovatel:
- Shyam Gupta, M.S. (OBGY)
-
Vrchní vyšetřovatel:
- Jishnu PS, MSc
-
-
Maharashtra
-
Pune, Maharashtra, Indie, 411014
- Indira IVF Hospital
-
Kontakt:
- Rajesh Bhisade, MSc
- Telefonní číslo: 919028034181
- E-mail: rajesh.bhisade@indiraivf.in
-
Dílčí vyšetřovatel:
- Amol Lunkad, M.S. (OBGY)
-
Vrchní vyšetřovatel:
- Rajesh Bhisade, MSc
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Males aged 21-55 years undergoing ICSI treatment for male factor infertility.
- Women with age 21-35 for self-oocyte pickup cycles
- Oocyte donor cycles with recipient age of 21-35 years of age
- Sperm with a minimum total motile sperm count of 2.0 million/mL and a minimum volume of 1.2 mL
- Patients not underwent sperm DNA fragmentation testing
- 2-3 days of abstinence prior to intracytoplasmic sperm injection (ICSI).
Exclusion Criteria:
- Severe male factor infertility (azoospermia or severe oligozoospermia; for this study defined as no sperm present or sample with <2 million/ml sperm count)
- Known systemic diseases (e.g., diabetes mellitus).
- Surgically retrieved sperms using testicular sperm aspiration, testicular sperm extraction and percutaneous epididymal sperm aspiration.
- Untreated endometrial or uterine factors or adnexal pathology
- Embryos underwent preimplantation genetic testing for aneuploidy testing.
- Patients with thin endometrium (<7mm)
- Patients opted or underwent donor sperms as the male gamete source.
- Patients underwent antioxidant treatment in last 6 months prior to ICSI treatment.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
ICSI Couples Undergoing SDF and dsSDF Assessment
Infertile couples undergoing intracytoplasmic sperm injection (ICSI) at participating tertiary IVF centres will be prospectively enrolled based on predefined eligibility criteria.
Semen samples collected on the day of ICSI will undergo assessment of global sperm DNA fragmentation (SDF) and double-strand sperm DNA fragmentation (dsSDF) using the LensHooke® X12 platform with the R10 Plus and R11 Plus kits, respectively.
SDF assessments will be performed before and after sperm preparation.
|
The LensHooke® X12 device is an automated sperm DNA fragmentation assessment platform based on the sperm chromatin dispersion (SCD) principle.
In this study, the device will be used to assess global sperm DNA fragmentation (SDF) and double-strand sperm DNA fragmentation (dsSDF) using the R10 Plus and R11 Plus kits, respectively.
The platform incorporates automated image acquisition and analysis to minimize operator-dependent variability and standardize sperm DNA fragmentation assessment.
Semen samples collected from participants undergoing intracytoplasmic sperm injection (ICSI) will be analysed before and after sperm preparation to evaluate the association between sperm DNA damage parameters and assisted reproductive technology (ART) outcomes.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Live Birth rate
Časové okno: 24 weeks post embryo transfer
|
Live birth will be defined as the delivery of one or more live infants at or beyond 24 weeks of gestation following embryo transfer.
Live birth rate will be calculated as the proportion of embryo transfer cycles resulting in at least one live birth.
|
24 weeks post embryo transfer
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Clinical Threshold Values for dsSDF and Global SDF
Časové okno: From fertilization assessment following intracytoplasmic sperm injection (ICSI) until live birth, approximately 18 months after participant enrolment.
|
Clinically relevant threshold values for double-strand sperm DNA fragmentation (dsSDF) and global sperm DNA fragmentation (SDF) will be derived using receiver operating characteristic (ROC) curve analysis based on their predictive ability for live birth and other assisted reproductive technology (ART) outcomes.
Thresholds will be identified as the values associated with a significant reduction in reproductive outcomes following intracytoplasmic sperm injection (ICSI).
|
From fertilization assessment following intracytoplasmic sperm injection (ICSI) until live birth, approximately 18 months after participant enrolment.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Vipin Chandra, M.B.B.S., D.G.O., Indira IVF Hospital Limited, India
- Ředitel studie: Sandro Esteves, Ph.D., Androfert Clinic, Brazil
- Studijní židle: Naval Shah, MSc, Indira IVF Hospital Limited, India
- Studijní židle: Shashank Sanagoudar, M.S. (OBGY), Indira IVF Hospital Limited, India
- Studijní židle: Divreena Talwar, MSc, Indira IVF Hospital Limited, India
- Studijní židle: Jayesh Shinde, MSc, Indira IVF Hospital Limited, India
- Studijní židle: Vivek Dave, Ph.D., Indira IVF Hospital Limited, India
- Studijní židle: Cherry Yang, MSc, Bonraybio Co. Ltd.
- Studijní židle: Tse-en Wang, Ph.D., Bonraybio Co. Ltd.
- Studijní židle: Santoshi Kadam, ADVY Chemical Private Limited
Publikace a užitečné odkazy
Obecné publikace
- Alvarez JG, Garcia-Peiro A, Barros A, Ferraz L, Sousa M, Sakkas D. Double strand DNA breaks in sperm: the bad guy in the crowd. J Assist Reprod Genet. 2023 Apr;40(4):745-751. doi: 10.1007/s10815-023-02748-5. Epub 2023 Feb 24.
- Agarwal A, Barbarosie C, Ambar R, Finelli R. The Impact of Single- and Double-Strand DNA Breaks in Human Spermatozoa on Assisted Reproduction. Int J Mol Sci. 2020 May 29;21(11):3882. doi: 10.3390/ijms21113882.
- Wang TE, Lee CI, Huang CC, Tsao HM, Chang HC, Chang LS, Chang TA, Lee MS, Hsu CT. Innovative technology for evaluation of sperm DNA double-strand breaks diagnoses male factor infertility and prevents reproductive failures. Sci Rep. 2023 Nov 3;13(1):18996. doi: 10.1038/s41598-023-46049-4.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- IIHL/EMB/PRS_001_2026
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .